Author + information
Cilotax stent is a dual drug-eluting stent (DES) designed to combination of paclitaxel and cilostazol for reducing the thrombosis using antiplatelet activity of the cilostazol. We evaluate the 3-years clinical outcomesbetween CILOTAX and everolimus-eluting stents (EES) in patients with STEMI.
A total of 2799 consecutive patients (pts) underwent percutaneous coronary intervention (PCI) due to STEMI using Cilotax (n=171) or EES (n=2628)were enrolled and 36-month clinical outcomes were compared between the two groups.
The baseline clinical and lesion characteristics were similar between the two groups except the EES group was older than Cilotax group (63 ± 12.4 vs. 59 ± 12.8, p < 0.001).The baseline lesion characteristics were similar between the two groups except the multivessel disease was more frequent in Cilotax group (44.9% vs. 56.7%, p < 0.05) whereas lesion length of the EES group was longer than Cilotax group (27.0 ± 11.3 mm vs. 20.1 ± 7.8 mm, p < 0.001). During 3-year follow-up, Cilotax group have higher incidence rates of target lesion revascularization (TLR), major adverse cardiac event (MACE) and stent thrombosis (ST) more than EES group (figure). Following adjustment for confounders, CILOTAX group was significantly associated with TLR (HR 3.49, 95% CI 1.75 to 6.98; p < 0.001), ST (HR 5.29, 95% CI 2.38 to 11.76; p < 0.001) and MACE (HR 1.64, 95% CI 1.11 to 1.43; p < 0.05) compare with EES group in the treatment of STEMI.
In the treatment of STEMI, patients treated with EES rather than CILOTAX experienced significantly improved event-free survival including MACE during 3-year follow-up period.